LWM
OVID icon

Lionsbridge Wealth Management’s Ovid Therapeutics OVID Stock Holding History

Lionsbridge Wealth Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-750
Closed -$2K – 236
2019
Q4 		$2K Buy
+750
New +$2.37K ﹤0.01% 189

Other funds holding OVID

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lionsbridge Wealth Management's OVID Position: Q1 2020 in Review

Lionsbridge Wealth Management sold out of Ovid Therapeutics (OVID) in Q1 2020, closing a stake of 750 shares — an estimated $2K sold.

Lionsbridge Wealth Management first reported a position in OVID in Q4 2019 and held it in 1 quarter. The position peaked at $2K in Q4 2019. 57 funds tracked by Wall St. Rank hold OVID as of Q1 2020.

  • Lionsbridge Wealth Management reported no remaining Ovid Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Lionsbridge Wealth Management sold 750 Ovid Therapeutics shares in Q1 2020, an estimated $2K.
  • Lionsbridge Wealth Management first reported a position in Ovid Therapeutics in Q4 2019 and held it in 1 quarter.
  • Lionsbridge Wealth Management's Ovid Therapeutics position peaked at $2K in Q4 2019.
  • 57 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2020.

Based on Lionsbridge Wealth Management's 13F filing for Q1 2020, filed 29 Apr 2020.